Clinical trials: Central Precocious Puberty (CPP)
Precocious, Leuprolide Acetate
Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty
The purpose of this extension study is to determine if leuprolide acetate (11.25 mg and 30 mg) is safe in treating children with Central Precocious Puberty over a longer period of time (36 months).
- Conditions
- Precocious, Leuprolide Acetate, Luteinizing Hormone (LH), Gonadotrophin-releasing Hormone Agonist (GnRHa)
- Trial name
- NCT00667446
- Testing
- Leuprolide Acetate 3 Month Depot
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 72 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Central Precocious Puberty (CPP)
A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)
The primary objective of the study is to assess the safety and efficacy of a leuprolide acetate (LA) 45 mg 6-month depot formulation for the treatment of CPP in children who are either naïve to treatment with a…
- Trial name
- NCT03695237
- Testing
- Leuprolide Acetate (LA)
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 45 people
- Sponsor
- AbbVie
Puberty, Precocious
A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty
The purpose of this study is to determine if 11.25 and 30 mg formulations of leuprolide are effective in treating children with Central Precocious Puberty (CPP).
- Trial name
- NCT00635817
- Testing
- Leuprolide acetate 11.25 mg, Leuprolide acetate 30 mg
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 84 people
- Sponsor
- Abbott
Central Precocious Puberty
A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants
The purpose of this study is to evaluate the long-term safety and efficacy of Enantone in the treatment of CPP in Chinese participants.
- Trial name
- NCT02993926
- Testing
- Enantone, GnRH agonist
- Where
- 6 sites in China
- Volunteers
- 108 people
- Sponsor
- Takeda
Central Precocious Puberty
A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty
The main aim is to see how leuprolide works to treat central precocious puberty in children. Participants will receive an injection of leuprorelin acetate depot 11.25 mg every 12 weeks during 6 months and will visit their study…
- Trial name
- PUPIL (NCT05341115)
- Testing
- Leuprorelin Acetate Depot 3M
- Where
- 5 sites in China
- Volunteers
- 79 people
- Sponsor
- Takeda
Puberty, Precocious
Study of Lupron Depot In The Treatment of Central Precocious Puberty
The purpose of this study is to determine if Lupron (leuprolide acetate) is safe and effective in treating children with Central Precocious Puberty (CPP), and to assess long term effects of leuprolide acetate treatment after…
- Trial name
- NCT00660010
- Testing
- Lupron (leuprolide acetate)
- Where
- 9 sites in United States
- Volunteers
- 55 people
- Sponsor
- Abbott